Oil prices rise on talk of Russia sanctions; bouncing off recent lows
SAN DIEGO—Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11.4 billion, executed several transactions involving the company's common stock, according to a recent SEC filing. The transactions come as the stock trades near its 52-week low of $110.95, with InvestingPro data indicating the stock is currently in oversold territory.
On February 13, Kyle sold a total of 2,558 shares of Neurocrine Biosciences stock. The sales were conducted in two separate transactions, with the first batch of 1,352 shares sold at an average price of $116.8448, totaling $157,974. The second batch, consisting of 1,206 shares, was sold at an average price of $116.8606, bringing in $140,933. Together, these sales amounted to a total value of $298,907. Despite these sales, the company maintains robust financial health, with InvestingPro analysis showing a strong current ratio of 3.4 and an overall financial health score rated as "GREAT."
In addition to the sales, Kyle also acquired shares through the exercise of stock options and restricted stock units. These acquisitions were made at no cost, adding a significant number of shares to his holdings.
Following these transactions, Kyle's direct ownership of Neurocrine Biosciences stock stands at 139,907 shares.
In other recent news, Neurocrine Biosciences experienced several adjustments in stock price targets from various financial institutions. Deutsche Bank (ETR:DBKGn) initiated coverage on Neurocrine's stock with a Hold rating and a price target of $138, citing the company's current market capitalization and the potential of its Ingrezza and Crensessity treatments. Meanwhile, UBS maintained a Buy rating but reduced the price target to $154, following a significant decline in the company's shares and lower-than-anticipated guidance for Ingrezza.
Guggenheim also maintained a Buy rating on Neurocrine but lowered the price target to $163 after the company's fourth-quarter sales report showed Ingrezza sales slightly below consensus estimates. Similarly, H.C. Wainwright adjusted the price target for Neurocrine to $185 while maintaining a Buy rating, following the announcement of Ingrezza's revenue and the company's conservative outlook for 2025.
These recent developments in the financial sector reflect the cautious optimism and conservative projections for Neurocrine Biosciences, particularly regarding the potential of its Ingrezza and Crensessity treatments. Despite the adjustments in price targets, the overall sentiment remains positive, with the potential for future growth and market penetration.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.